文章摘要
安伟乔 郜旭 吴秀萍 李艳敏 马丽芳.调脂治疗对老年高血压病动脉硬化事件的影响[J].,2014,14(29):5708-5711
调脂治疗对老年高血压病动脉硬化事件的影响
Effects of Rosurastain on Atherosclerotic Events in Elderly with Hypertension
  
DOI:
中文关键词: 老年人  动脉粥样硬化  瑞舒伐他汀  超敏C反应蛋白  白介素-10
英文关键词: Elderly  Atherosclerosis  Rosurastain  High sensitivity C-reactive protein  Interleukin-10(IL-10)
基金项目:黑龙江省教育厅科学技术研究项目(12521299)
作者单位
安伟乔 郜旭 吴秀萍 李艳敏 马丽芳 河北省邯郸市中心医院老年病科哈尔滨医科大学第一临床医学院老年病科 
摘要点击次数: 604
全文下载次数: 707
中文摘要:
      目的:观察瑞舒伐他汀调脂治疗12 周对80 岁以上老年高血压病患者的疗效、安全性以及对患者心脑血管终点事件的影响 及意义。方法:对44 例80 岁以上老年高血压患者根据血脂情况分为两组,均加用调脂药物(瑞舒伐他汀10 mg/d),观察用药的12 周前后,患者的血压情况,心脑血管事件的发生情况,并记录患者的血脂、超敏C反应蛋白(hs-CRP)、白介素-10(IL-10)、肝功能等 生化指标,进行比较。结果:两组治疗12 周后总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、超敏C 反应蛋白 (hs-CRP)均明显降低(P<0.01),且在血脂较高组降低的更明显(P<0.01),高密度脂蛋白胆固醇(HDL-C)、白介素-10(IL-10)均升高 (P<0.01),血压、脉压心脑血管终点事件在两组患者中均有下降(P<0.05),肝功能丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶 (AST)无明显变化(P>0.05)。结论:对于80 岁以上的老年高血压患者无论基础血脂水平如何,都有应用调脂药的必要。
英文摘要:
      Objective:To explore the effects and safety of rosuvastain in patients over 80 years old with hypertension and to observe the incidence of cardio-cerebral vascular events in 12 weeks.Methods:44 patients who were over 80 years old with hypertension were divided into two groups on the base of blood lipid level. They were all treated with rosuvastatain (10 mg/d) for 12 weeks. Blood pressure level, the incidence of cardio-cerebral vascular events, blood lipid, high sensitivity C-reactive protein (hs-CRP), interleukin 10 (IL-10), and liver function were recorded and compared.Results:All patients with medicines on average 12 weeks, the levels of LDL-C, TC, TG and hs-CRP decreased after rosuvastatin treatment (P<0.01). The levels of LDL-C, TC, TG and hs-CRP, the incidence of cardiocerebral vascular events were higher than before (P<0.01). The Ievels of HDL-C and IL-10 were higher (P<0.01). Blood pressure, pulse pressure and the incidence of cardio-cerebral vascular events decreased (P<0.05). All patients with medicines on average 12 weeks, aspartate aminotransferase andalanine aminotransferase with no statistically significant difference (P>0.05).Conclusion:Patients who were over 80 years old with hypertension, no matter which level of blood lipid, should be treated with rosuvastatain.
查看全文   查看/发表评论  下载PDF阅读器
关闭